Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development

Table 3 Logistic regression analysis of factors associated with decreased alpha-fetoprotein < 5 ng/mL 1 year after therapy among the patients showing alpha-fetoprotein ≥ 5 ng/mL before therapy

	Univariate analysis		Multivariate analysis
Factors	OR (range1)	P	OR (range1)	P
SVR patients
Age (1: ≥ 60 yr)	0.84 (0.50-1.4)	0.50
Gender (1: male)	1.3 (0.77-2.2)	0.32
HCV genotype	0.89 (0.54-1.5)	0.64
White blood cell (1: ≥ 4000/μL)	0.79 (0.43-1.5)	0.45
Hemoglobin (1: ≥ 12.5 g/dL)	0.55 (0.26-1.2)	0.12
Platelet count (1: ≥ 130000/μL)	1.2 (0.66-2.0)	0.60
ALT (1: ≥ 40 IU/L)	1.5 (0.82-2.8)	0.19
ALT at end of therapy (1: ≥ 40 IU/L)	0.86 (0.43-1.7)	0.68
ALT 1 yr after therapy (1: ≥ 40 IU/L)	0.27 (0.087-0.86)	0.027	0.27 (0.087-0.86)	0.027
Non-SVR patients
Age (1: ≥ 60 yr)	0.89 (0.55-1.4)	0.64
Gender (1: male)	1.2 (0.73-1.9)	0.53
HCV genotype	1.1 (0.59-2.2)	0.70
White blood cell (1: ≥ 4000/μL)	1.5 (0.86-2.7)	0.15
Hemoglobin (1: ≥ 12.5 g/dL)	1.6 (0.91-2.8)	0.10
Platelet count (1: ≥ 130000/μL)	1.8 (1.1-2.9)	0.019	1.5 (0.88-2.4)	0.14
ALT (1: ≥ 40 IU/L)	1.2 (0.69-2.1)	0.53
ALT at end of therapy (1: ≥ 40 IU/L)	0.31 (0.18-0.54)	< 0.0001	0.41 (0.22-0.75)	0.0040
ALT 1 yr after therapy (1: ≥ 40 IU/L)	0.35 (0.21-0.59)	< 0.0001	0.53 (0.30-0.93)	0.028

¹95%CI. SVR: Sustained virological response; HCV: Hepatitis C virus; ALT: Alanine aminotransferase.